Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
批准号:
8795307
负责人:
Elsa R Flores
金额:
$6.59万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2015-03-31
关键词:
AddressAllelesApoptosisApplications GrantsBiogenesisBrainBreast AdenocarcinomaCarcinomaCell MaintenanceCellsDNA DamageDataDevelopmentDisseminated Malignant NeoplasmDistant MetastasisEnzymesEpidermisFamilyFamily memberFinancial compensationFunctional RNAGenesGoalsHumanKnockout MiceLaboratoriesLengthLung AdenocarcinomaMalignant NeoplasmsMetastasis SuppressionMetastatic CarcinomaMetastatic Skin CancerMetastatic Squamous Cell CarcinomaMicroRNAsMorphogenesisMusNatureNeoplasm MetastasisPathway interactionsPatientsPlayPositioning AttributeProcessProtein IsoformsPublishingRegulationResearchRoleSamplingSkinSkin CancerSquamous cell carcinomaStem cellsSystemTherapeutic InterventionTransactivationTranscriptional RegulationTumor Suppressioncancer therapyhuman DICER1 proteinimprovedin vivoinnovationmortalitymouse modelmutantnovelresponseskin squamous cell carcinomastemtumortumorigenesistumorigenic
中文摘要
描述(申请人提供):癌症的死亡率最常见的原因是远处转移的发展,对此几乎没有有效的系统治疗方法。因此,研究与体内转移调控相关的基因具有重要意义。P63是P53家族成员之一,在P53功能已经确立的背景下,人们开始了解P63的功能,包括凋亡和肿瘤抑制(Su等人,自然2010),以及其他角色,如转移(Su等人,自然2010)、皮肤发育和干细胞维持(Su等人,Cell Stem Cell,2009)。P63功能的复杂性部分是由于存在以前无法独立研究的多种异构体。P63的全长TA异构体含有一个结构和功能类似于P53的反式激活结构域,而P63的?N异构体在具有反式激活活性的同时,拮抗P53和P63和P73的TA异构体的活性。有趣的是,突变型p53存在于多种人类癌症中,已被证明与p63亚型相互作用并使其功能失活。通过建立和研究p63等位基因缺失的小鼠,TAp63-/-和?Np63-/-小鼠,我们已经证明这些基因在抑制肿瘤的发生和转移方面有不同的作用。TAp63-/-小鼠对自发转移的肿瘤高度敏感,TAp63通过直接协调DICER和几个miRNAs的转录调控而有效地抑制肿瘤转移(Su等人,自然2010)。此外,我们已经将这些发现扩展到包括鳞状细胞癌、肺腺癌和乳腺癌在内的多种人类肿瘤类型,表明TAp63的这一功能具有广泛的重要性。我们还表明,Np63可以抑制入侵并在转录上调节Dgcr8,这是另一种对miRNA加工至关重要的酶。我们假设TAp63和?Np63在不同的细胞内调节不同的miRNAs,以抑制肿瘤的发生和转移,并参与DNA损伤反应。我们将通过提出以下特定目标来解决我们的假设:特定目标1:了解肿瘤起源细胞(表皮细胞)中p63亚型对miRNA和LincRNA靶标的机制调控。具体目的2:了解皮肤癌和转移干细胞中p63亚型对miRNAs和lincRNAs的调控机制。具体目的3:了解p63亚型调控的miRNAs和lincRNAs在DNA损伤反应和P53代偿中的作用。
英文摘要
DESCRIPTION (provided by applicant): Mortality in cancer is most often due to the development of distant metastases for which almost no effective systemic treatments exist. The study of genes relevant for the regulation of metastasis in vivo is therefore of great importance. The functions of p63, a p53 family member, are beginning to be understood in contexts in which p53 function has been well established, including apoptosis and tumor suppression (Su et al., Nature 2010) as well as in other roles such as metastasis (Su et al., Nature 2010), skin development, and stem cell maintenance (Su et al., Cell Stem Cell 2009). The complexity of p63 function is due in part to the existence of multiple isoforms that previously could not be studied independently. Full length TA isoforms of p63 contain a transactivation domain, structurally and functionally resembling p53, whereas the ?N isoforms of p63, while also possessing transactivation activity, antagonize the activities of p53 and the TA isoforms of p63 and p73, the other p53 family member. Interestingly, mutant p53, present in a wide variety of human cancers, has been shown to interact with p63 isoforms and inactivate their function. By generating and studying mice with isoform-specific null alleles of p63, the TAp63-/- and ?Np63-/- mice, we have shown that these genes have distinct roles in suppression of tumorigenesis and metastasis. TAp63-/- mice are highly susceptible to spontaneous metastatic tumors, and TAp63 potently suppresses tumor metastasis by direct coordinate transcriptional regulation of Dicer and several miRNAs (Su et al., Nature 2010). In addition, we have extended these findings to multiple human tumor types including squamous cell carcinoma, lung adenocarcinoma, and breast adenocarcinoma, indicating this function of TAp63 is widely important. We have also shown that ?Np63 can suppress invasion and transcriptionally regulates DGCR8, another critically important enzyme necessary for miRNA processing. We hypothesize that TAp63 and ?Np63 regulate distinct miRNAs in different cellular compartments to suppress tumorigenesis and metastasis and to engage the DNA damage response. We will address our hypothesis by proposing the following specific aims: Specific Aim 1: To understand the mechanistic regulation of miRNA and LincRNA targets by p63 isoforms in the cell of origin of carcinomas (epidermal cells). Specific Aim 2: To understand the mechanistic regulation of miRNAs and LincRNAs by p63 isoforms in stem cells of skin cancer and metastasis. Specific Aim 3: To understand the roles of miRNAs and LincRNAs regulated by p63 isoforms in the DNA damage response and p53 compensation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1
-
批准号:10171099
-
项目类别:
-
资助金额:$23.72万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Project 1
-
批准号:10438713
-
项目类别:
-
资助金额:$23.2万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Administrative Core
-
批准号:10438717
-
项目类别:
-
资助金额:$9.85万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Administrative Core
-
批准号:10171103
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Identifying Metabolic Vulnerabilities in Lung Cancer
-
批准号:10438711
-
项目类别:
-
资助金额:$202.9万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Identifying Metabolic Vulnerabilities in Lung Cancer
-
批准号:10171098
-
项目类别:
-
资助金额:$206.0万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Project 1
-
批准号:10676731
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Identifying Metabolic Vulnerabilities in Lung Cancer
-
批准号:10676730
-
项目类别:
-
资助金额:$201.92万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Administrative Core
-
批准号:10676745
-
项目类别:
-
资助金额:$10.16万
-
财政年份:2021
-
负责人:Elsa R Flores
-
依托单位:
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
-
批准号:9903249
-
项目类别:
-
资助金额:$92.16万
-
财政年份:2016
-
负责人:Elsa R Flores
-
依托单位:
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
-
批准号:10132250
-
项目类别:
-
资助金额:$93.88万
-
财政年份:2016
-
负责人:Elsa R Flores
-
依托单位:
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
-
批准号:9264501
-
项目类别:
-
资助金额:$90.44万
-
财政年份:2016
-
负责人:Elsa R Flores
-
依托单位:
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
-
批准号:10380625
-
项目类别:
-
资助金额:$90.17万
-
财政年份:2016
-
负责人:Elsa R Flores
-
依托单位:
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
-
批准号:8297085
-
项目类别:
-
资助金额:$50.15万
-
财政年份:2012
-
负责人:Elsa R Flores
-
依托单位:
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
-
批准号:8461599
-
项目类别:
-
资助金额:$45.74万
-
财政年份:2012
-
负责人:Elsa R Flores
-
依托单位:
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
-
批准号:8831609
-
项目类别:
-
资助金额:$47.62万
-
财政年份:2012
-
负责人:Elsa R Flores
-
依托单位:
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
-
批准号:8642610
-
项目类别:
-
资助金额:$42.57万
-
财政年份:2012
-
负责人:Elsa R Flores
-
依托单位:
Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer
-
批准号:8654057
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2012
-
负责人:Elsa R Flores
-
依托单位:
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis
-
批准号:8205003
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2009
-
负责人:Elsa R Flores
-
依托单位:
Investigating the role of p73 and its isoforms in tumorigenesis and metastasis
-
批准号:8006441
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2009
-
负责人:Elsa R Flores
-
依托单位:
海外基金